Introduction
Patients with chronic kidney disease (CKD) are prone to protein-energy wasting (PEW), which is associated with a poor prognosis [1, 2] . The loss of the desire to eat-an-orexia-is one of the most common symptoms of uraemic PEW, and is progressively associated with worse renal function, higher hospitalization rates and worse outcomes [3, 4] . Visfatin, recently described as a novel adipokine [5] , is also known as nicotinamide phosphoribosyltransferase (NAMPT) that is a ubiquitously expressed intracellular protein linked to cellular energy homeostasis, and is the rate-limiting step for cell synthesis of nicotinamide adenine dinucleotide [6] . Extracellular visfatin was recently suggested to be upregulated in times of low-nutrient availability [7] , regulating appetite in both animal and human studies [8, 9] and promoting cell survival during starvation [6] . Indeed, as opposed to serum visfatin levels, visfatin concentrations in human cerebrospinal fluid (CSF) decrease with rising body fat, leading to the hypothesis that centrally acting visfatin is linked to the development of obesity, and reduced CSF visfatin or the development of resistance to its effects may play a role in altered body weight regulation [10] . Further support for this hypothesis comes from reports linking rare polymorphisms of the visfatin gene to protection from obesity [11, 12] .
In uraemia, we have recently reported that circulating NAMPT/visfatin is a strong predictor of the endothelial dysfunction commonly found in these patients [13] [14] [15] . However, to our knowledge, no studies have yet investigated the putatively metabolic role of visfatin in CKD. In this hypothesis-generating study, we tested the possible involvement of visfatin in the regulation of appetite and nutrient homeostasis in patients with CKD. We thus measured circulating visfatin and two polymorphisms of the visfatin gene in 246 incident CKD stage 5 patients starting dialysis therapy and related the data to subjective and objective markers of nutrient intake.
Methods

Patients
The patients in the present study were included in an ongoing prospective cohort study including incident patients who are beginning dialysis replacement therapy at the Renal Clinic of the Karolinska University Hospital Huddinge, Stockholm, Sweden [16] . In the present study, post hoc analyses of 246 CKD stage 5 patients (151 men) with a median age of 56years (IQ range: 44-64years) and a median glomerular filtration rate (GFR) of 6.3mL/min (IQ range: 4.9-7.9mL/min) were conducted. Exclusion criteria were age >70years, liver dysfunction, clinical signs of intercurrent infection and unwillingness to participate in the study. Causes of CKD were chronic glomerulonephritis in 65 patients, diabetic nephropathy in 77 patients, polycystic kidney disease in 26 patients, nephrosclerosis in six patients and other or unknown in 72 patients. In accordance with current therapy recommendations, most of the patients initially taking oral antiglycaemic agents or on restricted diets had been switched to insulin therapy at the time of inclusion in the study. The majority of patients were on antihypertensive medications (angiotensin-converting enzyme [ACE] inhibitors and/or angiotensin II receptor antagonists, n=123; beta-blockers, n=143; calcium channel blockers, n=99) and other commonly used drugs in CKD, such as phosphate and potassium binders, diuretics, erythropoiesis-stimulating agents, iron substitution and vitamin B, C and D supplementation. Forty-eight patients (19%) were on lipid-lowering medication (HMGCoA reductase inhibitors). Fifty-seven (23%) patients were taking essential amino acid supplements at the time of inclusion. The protocol was approved by the Ethics Committee of the Karolinska Institutet at the Karolinska University Hospital Huddinge, Stockholm, Sweden, and informed consent was obtained from each patient.
Nutritional status
Self-reported appetite is a part of the subjective global assessment questionnaire (SGA) [17] , which was recorded at the time of inclusion, concurrent with the drawing of blood samples. We have previously demonstrated the validity of this self-reported appetite assessment [18] where all patients were asked to grade their appetite themselves according to the following scale: 1=good, 2=sometimes bad, 3=often bad and 4= always bad. In the following analyses, categories 3 and 4 were grouped together as 'poor appetite' for simplification purposes. In some cases, dichotomization into presence or absence (categories 2-4) of appetite loss was also performed. Body mass index (BMI) was calculated as weight (in kilograms)/height [2] . Handgrip strength was measured using a Harpenden handgrip dynamometer (Yamar, Jackson, MI, USA) in both the dominant and non-dominant arms. Each measurement was repeated three times in each arm, and the highest value for each arm was noted. For our analysis, we used the highest result obtained.
Biochemical measurements
After an overnight fast, venous blood samples were drawn and stored at −70°C for biochemical analyses. Evaluation of serum visfatin levels was performed by using a C-terminal (human) enzyme-linked immunosorbent assay (ELISA) kit from Phoenix Pharmaceuticals Inc. (Belmont, CA, USA) with a reported sensitivity of 1.89ng/mL. Following the protocol provided by the manufacturer, the intra-assay variability was <5% and interassay variability was <14%. Plasma amino acid concentrations were measured with the use of reversed-phase high-performance liquid chromatography and fluorometric detection, as described elsewhere [19] . The routine procedures used in the Clinical Chemistry Laboratory at Huddinge University Hospital were used to measure serum concentrations of albumin (bromcresol purple), high-sensitivity CRP (hs-CRP, by nephelometry), serum cholesterol and triacylglycerols (Roche Diagnostics GmbH). The serum concentration of interleukin-6 (IL-6) was measured with a photometric ELISA (Boehringer Mannheim, Mannheim, Germany). Measurements of soluble vascular cell adhesion molecule-1 and long pentraxin-3 were also performed with commercial kits (R&D Systems Europe Ltd, Abington, UK and Perseus Proteomics, Tokyo, Japan, respectively). GFR was estimated as the mean of urea and creatinine clearance obtained from a 24-h urine collection.
Visfatin genotyping
We analysed two validated single-nucleotide polymorphisms (SNPs) with a minor allele frequency of ≥5%: rs1319501 (−423 A/G) and rs9770242 (−1001T/G), as described in the National Center of Biotechnology Information Database (www.ncbi.nlm.nih.gov). Genomic DNA was extracted from a 5-mL EDTA sample of peripheral blood by using QIAamp DNA kit (Qiagen, Valencia, CA) in 206 of the patients, while 40 patients lacked a stored whole blood sample. Samples were stored at −20°C. Primers for polymerase chain reaction (−423 A/G forward 5′-GGG GAG GAG GAC GTG ATG-3′ and reverse 5′-TGC CGG GAA CTC GAA CTTA-3′; 1001 T/G forward 5′-CGG GAA GGA AAA GCG AACG-3′ and reverse 5′-CGC AAG TCT TTC TTG GAA TGGT-3′) and sequencing primers (−423 A/G 5′-CTT AGG TAA GCG CCC-3′ and −1001 G/T 5′-TAA CGA TGA TAA AAG TCA GT-3′) were designed according to the Pyrosequencing Assay Design Software, version 1.0 (Biotage AB, Uppsala, Sweden), and sequencing was performed on a PSQ 96MA instrument (Biotage AB) [20] . All oligonucleotides were purchased from Thermo Electron Corporation (Ulm, Germany). For sample preparation, the PSQ 96 Sample Prep Tool was used. Because calculation of linkage disequilibrium between the two SNPs showed that the −423 and −1001 alleles were completely linked (D′=1; r 2 =0.98), only the results for the −1001 T/ G variant will be shown. Both SNPs fulfilled the assumptions of the Hardy-Weinberg equilibrium in the patient cohort.
Statistical analyses
Normally distributed variables were expressed as means±SDs (unless otherwise noted), and non-normally distributed variables were expressed as medians and interquartile ranges (IQR). Statistical significance was set at the level of P<0.05. Comparisons between two groups were assessed with the Student's unpaired t-test, Mann-Whitney test or χ 2 test as appropriate. Differences among more than two groups were analysed by the Kruskal-Wallis test. Spearman's rank correlation (ρ) was used to determine correlations of visfatin with other variables. Fifty-seven (23%) patients were taking amino acid supplements (receiving a mix of essential amino acids) at the time of inclusion, but we did not consider this as a confounder since previous literature reported that the association between visfatin and nutrient intake may be bi-directional [8, 9] . Statistical analyses were performed using statistical software JMP, version 7.0.1 (SAS Institute, Cary, NC). Evaluation of Hardy-Weinberg equilibrium was performed for the two polymorphisms by using the DeFinetti procedure (http://ihg.gsf.de).
Results
Median serum visfatin concentrations were 31. Univariate correlates for circulating visfatin and relevant parameters are included in Table 1 , model 1. Visfatin was positively correlated with age, and no association was found with fat mass (both BMI and leptin). Negative associations were found for plasma amino acids (both essential and non-essential), blood lipids (cholesterol and triglycerides) and albumin. Visfatin shared statistically significant negative associations with several non-essential (asparagine, glutamine, glycine, citrulline, arginine, alanine, ornithine) and essential amino acids (histidine, tyrosine, methionine, tryptophan, phenylalanine), being the strongest for arginine (ρ=−0.31; P<0.0001) and histidine (ρ=−0.27; P<0.0001). We also performed the same correlations excluding diabetic patients (Table 1, model 2), which did not alter the results significantly.
Patients were also divided according to tertiles of visfatin, and the clinical characteristics of each group are shown in Table 2 . Briefly, higher visfatin was associated with an increased prevalence of diabetes and a greater proportion of patients reporting loss of appetite as well as lower circulating albumin, cholesterol and triglyceride concentrations. Data presented in Table 3 show that, with increasing visfatin tertiles, there was a significant decrease in most serum non-essential (NEAAs) and essential (EAAs) amino acid concentrations, resulting in a significant decrease in total serum amino acid levels.
Visfatin levels proved to be higher in patients reporting poor appetite (Figure 1) . No difference in age, sex, GFR, diabetes or BMI was found across the appetite categories (data not shown). Across worsening appetite, patients were more often wasted (SGA>1; P<0.0001) and with a bigger proportion of patients with a history of CVD (P<0.01). Interestingly, the −1001 T/G (rs9770242) SNP in the upstream region of the visfatin gene was associated with significantly different visfatin levels (Figure 2A ). Patients carrying one or two T-alleles displayed higher serum visfatin concentrations, and a greater proportion of the pa- Visfatin levels and appetite loss in CKDtients with G/T or T/T genotypes reported appetite loss ( Figure 2B ).
Discussion
In a cross-sectional study of patients with advanced CKD, we report that elevated circulating visfatin is associated with self-reported appetite loss and decreased circulating levels of amino acids and triacylglycerols. Furthermore, a gene polymorphism associated with increased circulating visfatin was also found to be related to appetite loss. As anorexia is common in CKD, correlates of a poor appetite are of interest. In the present study, a high circulating visfatin was associated with a decreased appetite. A role for visfatin in appetite regulation has not been previously suggested in CKD, but it was recently reported that a hypocaloric diet in pre-menopausal women results in an increase of visfatin mRNA expression in adipose tissue [21] , whereas 7 days of overfeeding reduced circulating visfatin by 20% in a cohort of healthy men [9] . Additionally, animal studies have shown that visfatin is elevated and acts as an important regulator of cell survival in fasting rodents [6] , while intracerebral visfatin injections induce feeding behavior in chicks [8] . These data have found a human correlate with a recent paper reporting that visfatin concentrations in human CSF decrease with rising body fat, while circulating visfatin levels increase, leading to the speculation that visfatin resistance or reduced intracerebral accumulation may be pathophysiologically linked to obesity [10] . In the present study, serum visfatin concentrations were considerably higher than those reported by Hallschmid et al. [10] in healthy and obese subjects but still related to both objective markers of nutrient intake and to self-reported appetite. Indeed, high circulating visfatin levels were associated with low fasting blood triacylglycerols, low total cholesterol and low systemic levels of serum amino acids, especially NEAAs. This latter finding may be explained by earlier studies that have shown that NEAAs in the circulation are higher in well-nourished CKD stage 5 patients [22] , perhaps due to a selective decrease in splanchnic NEAA uptake [23] . Our results are also similar to and complementary of the findings by Sun et al. [9] , who found that fasting visfatin concentrations were associated with serum triacylglycerols in healthy men.
Appetite is a short-term sensation that determines subsequent food intake [3, 4] and, together with measures of fasting amino acids or lipids (indirectly reflecting immediate dietary intake), should not be confused with markers of long-term starvation. In our study, increased visfatin levels relate with such markers of short-term intake but not with BMI, handgrip strength or SGA, which are likely the consequence of a prolonged period of wasting/starvation leading to a state of PEW. In fact, in accordance with our results, several well-powered observational studies have found no apparent changes in surrogate markers of PEW, including BMI (which is also influenced by hydration status), muscle mass and handgrip strength, across different self-reported appetite categories in haemodialysis patients [24, 25] , although in each of these studies poor appetite significantly predicted a poor outcome [24, 25] . Interestingly, patients in the present study that reported a decreased appetite also had elevated serum visfatin concentrations and carried one or two copies of the T-allele of the −1001 T/G (rs9770242) variant in the upstream region of the visfatin gene. This polymorphism, which is in complete linkage disequilibrium with the rs1319501 variant, has been previously associated with increased insulin sensitivity [26] and serum visfatin concentrations [13] . In support of our findings, rare variants in the visfatin gene have also been reported to be associated with body weight [11, 12] .
While our data would seem to encourage further investigation into the role of visfatin in uraemic anorexia, several important weaknesses should be discussed. First, the cross-sectional design precludes the inference of causality, and our results are based on a relatively small cohort. Furthermore, a self-reported appetite questionnaire such as the one we used is potentially influenced by subjective and psychological factors, but a number of recent studies have validated this simple approach in dialysis patients [18, 24, 25, 27] , observing a consistent agreement with more classical methods of appetite assessment, including visual analogue scales [28] . Finally, and given visfatin's ubiquitous expression [6] , it is not surprising that the present study, like most [13] [14] [15] 29] but not all [30] recent reports in dialysis patients, failed to find any association of visfatin with BMI or visceral fat. Our study also did not show an association with leptin. Thus, it may be inaccurate to refer to visfatin as an adipokine or even a pseudo-adipokine.
In summary, we report novel associations between visfatin and both subjective assessment of appetite and biochemical markers reflecting nutrient intake in incident CKD stage 5 patients. Based on recent studies in non-uremic individuals, we speculate that a high serum visfatin in CKD patients may constitute a counter-regulatory response to central visfatin resistance or, alternatively, resistance to other unmeasured orexigenic compounds that accumulate in uremia. Future studies should examine a putative role of visfatin as a regulator of nutrient homeostasis in uremia. The sample distribution among the genotypes is: G/G, n=13; G/ T, n=75; T/T, n=118. Non-parametric Kruskal-Wallis test was used to denote differences among the groups considered. Self reports of appetite were dichotomized into presence or absence of appetite loss (see Methods).
